Introduction
The mitochondria are double-membrane intracellular organelles. On the inner mitochondrial membrane, the respiratory chain consisting of five complexes is situated, which, by a process called oxidative phosphorylation, synthesize ATP, essential to all active intracellular processes. Depending on the energy demand of the cell, the amount of mitochondria varies between tissues. This explains why mitochondrial diseases affect the functioning of some organs more often than others. With the biosynthetic and the detoxifying characteristics of the liver being highly dependent on ATP, it is not surprising that the hepatocytes are packed with mitochondria and hence are very susceptible to mitochondrial dysfunction. Other tissues that are often affected by mitochondrial diseases are, in order of importance, muscle (skeletal and heart), the central and peripheral nervous system (including vision and hearing), kidney, pancreas, and bone marrow [1] . Each of the five complexes of the respiratory chain contains several subcomplexes, of which only 13 are encoded by mitochondrial DNA (mtDNA). Nuclear genes, in contrast, encode more than 70 subunits, as well as multiple enzymes and cofactors required to maintain mtDNA [2] . These nuclear genes include DNA polymerase g (PolG) and thymidine phosphorylase (TP). Mutations in both mtDNA and nuclear DNA can cause dysfunction of the respiratory chain, which directly influences energy metabolism and fatty acid oxidation within the hepatocytes, resulting in impaired bile flow and steatosis, cell death, and fibrogenesis [2] . Mitochondrial disorders affect about 1/5000-1/10 000 individuals [1] . In a population-based study of the prevalence of mitochondrial encephalomyopathies in Sweden, liver involvement was noted in 20% of the cases studied. Sokol and Treem [3] have proposed a classification scheme for mitochondrial hepatopathies ( Table 1) that includes primary disorders, in which the mitochondrial defect is the primary cause of the liver disorder, and secondary disorders, in which a secondary insult to mitochondria is caused either by a genetic defect that affects nonmitochondrial proteins or by an acquired (exogenous) injury to mitochondria. Leonard and Shapiro [4] have further divided primary mitochondrial diseases into those caused by mutations affecting mtDNA genes (class 1a) and those caused by mutations in nuclear genes that encode mitochondrial respiratory chain proteins or cofactors (class 1b).
Mitochondrial DNA depletion syndromes (MDS), that is, syndromes in which the amount of mtDNA is decreased, can present with two different clinical phenotypes: a myopathic and a hepatocerebral form. The latter form can be caused by mutations in MPV17, deoxyguanosine kinase (DGUOK), and PolG. MPV17 mutations cause Navajo neurohepatopathy (progressive cirrhosis and liver failure with death in early childhood). DGUOK mutations cause a very rare but severe form of MDS. Both MPV17 and DGUOK typically present within the first weeks of life with hepatomegaly and progressive liver failure leading to death a few months later [5] [6] [7] . PolG mutations underlie the more frequent Alpers-Huttenlocher syndrome (AHS), in which liver disease usually starts later in life, often with extrahepatic symptoms masking hepatopathy at the beginning. Mutations in TP are the most frequent cause of the clinical syndrome mitochondrial neurogastrointestinal encephalopathy (MNGIE) and can either result in mtDNA depletion, multiple deletions, or both.
The aim of this article is to discuss the broad clinical spectrum of mitochondrial diseases. Moreover, the spectrum of mitochondrial hepatopathies is supported by the present literature and illustrated by four cases diagnosed between 2005 and 2010 in our university referral center. Through these case studies, we focus on two particular genes, PolG and TP, that can cause respiratory chain disorders as mutations in these genes are considered to be the most frequent causes of mitochondrial hepatopathy in adults.
Case description
Case 1 A 28-year-old woman presented with a multiple sclerosislike episode of cerebellar syndrome, left pyramidal syndrome, vertigo, and partial epilepsia. Later on, Wilson's disease was suspected because of an elevated urine copper dosage, a positive D-penicillamine challenge test, and an elevated copper content in the liver [915 mg/g, upper limit of normal (ULN) 50 mg/g]. However, no Kayser-Fleischer ring was visualized, serum ceruloplasmin was not decreased, and genetic screening for Wilson's was negative. Ultrasound (US) and computed tomography (CT) showed normal density of the liver, with no arguments for Wilson's disease or for steatosis. Brain MRI showed significant white matter lesions, from which a biopsy was taken, which was not diagnostic. Electromyography showed possible peripheral nerve damage. Epileptic episodes were occasionally treated with valproic acid (VPA) in the acute setting. Several episodes of hepatitis were noted during the following years, with mildly elevated aspartate aminotransferase (AST) (max. 2 Â ULN), alanine aminotransferase (ALT) (max. 6 Â ULN), g glutamyl transpeptidase (gGT) (max. 3 Â ULN), and alkaline phosphatase (AF) (max. 1.5 Â ULN). Plasma lactic acid was chronically mildly elevated between 2 and 3 mmol/l (ULN 2.0 mmol/l). Lactic acid in the cerebrospinal fluid (CSF) remained within the normal range. A second liver biopsy showed normal parenchyma with perisinusoidal fibrosis without arguments for nonalcoholic steatohepatitis or Wilson's disease. Further genetic investigation showed that the patient was homozygous for the PolG mutation Trp748Ser, a mutation known to cause AHS. Five years after the first medical contact, she died during a status epilepticus. Liver tests were mildly elevated at that time. Autopsy showed an enlarged liver of 2080 g with microvesicular steatosis and extended necrosis of hepatocytes with congestion, a picture resembling shock liver.
Case 2
This 48-year-old cachectic woman presented with a pyramidal syndrome since 10 years. In the following years, she developed episodes of jaundice and hepatitis without a clear etiology, with AST and ALT levels higher than 1000 U/l. MRI of the brain showed diffuse white matter lesions, which led to a diagnosis of multiple sclerosis. She received treatment with pulses of glucocorticoids, which resulted in a good response. Biochemically, elevated intermediates of the tricarboxylic acid cycle were found in the urine. Plasma lactic acid was found to be normal, as was the lactic acid/pyruvate ratio. US showed an enlarged liver with steatosis. Liver biopsy showed Metavir fibrosis stage III (septal fibrosis, the stage preceding cirrhosis, i.e. Metavir stage IV), and spectrophotometric determination of respiratory chain complex activities showed decreased mitochondrial respiratory chain complex II and III activity in liver tissue. Electron microscopy showed the presence of curled cristae and a dark matrix in some hepatic mitochondria. Genetic screening of PolG showed a heterozygous mutation Asn468Asp in exon 7, an autosomal dominant mutation known to cause AHS. Family history showed that two of her three sisters had died after a premature birth. One of her sons has a mental delay after premature birth at 7 months, and the proband's mother showed similar symptoms of frequent stumbling since the age of 50.
Case 3
A 21-year-old woman presented with an acute grand-mal epileptic episode, for which she was treated with among other VPA. The next day, however, she developed a status epilepticus, after which diphenylhydantoine and acyclovir were associated. Shortly after, she underwent urgent surgery with right hemicolectomy and ileostoma for an acute abdomen with a dilated megacolon without a clear cause. Electromyography indicated polyneuropathy. Several episodes of elevated liver enzymes were noted in the following months (AST max. 8 Â ULN, ALT max. 4 Â ULN, gGT max. 13 Â ULN, AF max. 1.5 Â ULN). VPA and diphenylhydantoine were stopped, resulting in a moderate improvement in the liver tests. US and CT showed enlargement of the liver with normal density. Plasma lactic acid was chronically elevated (max. 3.71 mmol/l, ULN 2.00 mmol/l), as was lactic acid in the CSF (max. 3.35 mmol/l, ULN 2.20 mmol/l). The lactic acid/pyruvate ratio was 30.1 (ULN 20) . A maternal aunt of this patient had already been diagnosed with polyneuropathy caused by a homozygous recessive Ala467Thr mutation in the PolG gene. Screening in our patient indicated homozygosity for the same mutation. The patient developed several episodes of status epilepticus and infectious complications later in life and died at the age of 21 from sepsis.
Case 4
This 36-year-old woman presented with anorexia, abdominal distension, postprandial abdominal pain, postprandial nausea and vomiting, sporadical diarrhea, and fatigue since several months. In the following years, she developed severe malnutrition, multiple small intestinal bowel diverticules complicated with perforation, lactose intolerance, and malabsorption syndrome with the need of gastrostomy and afterwards total parenteral nutrition. Clinically, external ophthalmoplegia, ptosis, myopathy, and polyneuropathy were observed. Radiography of the abdomen suggested recurring (pseudo)obstruction. US of the abdomen at first showed liver steatosis, progressively evolving to cirrhosis. Liver function tests were mainly cholestatic, with gGT (max. 14 Â ULN), AF (max. 15 Â ULN), and bilirubin (max. 5 Â ULN) being significantly elevated. AST (max. 3 Â ULN) and ALT (max. 1.5 Â ULN) were only mildly elevated. Blood results showed a chronically elevated lactic acid (max. 6.75 mmol/l, ULN 2.0 mmol/l). The lactic acid/pyruvate ratio was 39.1 (ULN 20) . Muscle biopsy showed no ragged-red fibers and normal mitochondrial respiratory chain complexes. Jejunal biopsy indicated visceral myopathy with nonspecific inflammation. Liver biopsy showed perivenous fibrosis, and limited microvacuolar and macrovacuolar steatosis. PolG investigation showed no pathological mutations. However, TP enzymatic deficiency as well as two mutations in the TP gene were found (homozygous for c.215G > A), confirming the diagnosis of MNGIE. Transplantation of the liver, bone marrow, and/or small bowel was suggested. However, total parenteral nutrition caused her untimely death through recurrent episodes of catheter-related sepsis before any transplantation could be performed. We note that her first child was born prematurely at 27 weeks and died of acute respiratory distress syndrome. Her brother died after an anamnestically similar process.
Alpers-Huttenlocher syndrome and mitochondrial neurogastrointestinal encephalomyopathy
The nuclear gene defects most often causing AHS are located in the PolG gene, which encodes a DNA polymerase that is responsible for replicating and repairing mtDNA. Mutations in this gene can cause accumulation of 'mistakes' and eventually depletion of mtDNA. The hallmark features of AHS include the clinical triad of refractory seizures, psychomotor retardation, and hepatopathy. The typical age of onset of AHS is between 2 and 4 years of age, but can range from 3 months up until the fourth decade. Our second patient was 48 years old at first presentation. However, it should be noted that the initial problems had started 10 years ago. In children, seizures with no typical semiology are the first clear sign of AHS in about 50% of the patients [6] . In 75% of cases, periods of psychomotor retardation, failure to thrive, and hypotonia already preceded [7] . AHS is a progressive disorder and often leads to death from status epilepticus or hepatic failure. Other symptoms include migrainous headaches, most often associated with visual hallucinations, which reflect early occipital lobe dysfunction [8] , Parkinsonian syndrome, ataxia, neuropathy, cognitive impairment, blindness because of cortical visual loss and, less importantly, retinopathy, short stature, and even gastrointestinal pseudoobstruction with dysmotility [9] . AHS is just one possible phenotype of a broad spectrum caused by mutations in PolG. Depending on the kind of mutation and the amount of different mutations in this gene, other syndromes are possible (childhood myocerebrohepatopathy spectrum disorders, ataxia neuropathy spectrum disorders, myoclonic epilepsy myopathy sensory ataxia, autosomal recessive progressive external ophthalmoplegia, and autosomal dominant progressive external ophthalmoplegia).
MNGIE is caused by loss-of-function mutations in the nuclear gene encoding TP. TP is involved in regulating intramitochondrial nucleoside pools, thus providing a source for continual synthesis of mtDNA. MNGIE is an autosomal recessive disorder with onset typically later than in most mitochondrial disorders: between the second and the fifth decade. Typical clinical features are (a) severe gastrointestinal dysmotility (often pseudoobstruction), (b) cachexia, (c) ptosis, (d) external ophthalmoplegia, (e) sensorimotor neuropathy, and (f) diffuse leukoencephalopathy [10] .
The estimate of patients affected by AHS is B1/ 51 000 [11] . The percentage of carriers of just one known point mutation resulting in the pathogenic allele Ala467Thr (cf. case 3) that causes AHS is already 0.6% in Belgium [12] and up to 1% in Norway [13] . This probably makes PolG mutations one of the most common causes of inherited mitochondrial disease in children and adults. MNGIE, in contrast, is a rare condition, with less than 200 patients described. Because of the highly variable prevalence of carriers between different regions, estimates are difficult to generalize. Moreover, because of clinical heterogeneity and diagnostic difficulties, most suggested numbers are likely to be an underestimate of the true prevalence.
Clinical spectrum of liver damage in mitochondrial diseases
Mitochondrial hepatopathy covers almost every possible presentation, ranging from acute neonatal liver failure to insidious-onset hepatic steatosis progressing to chronic liver disease with cholestasis. In many known mitochondrial syndromes, hepatopathy presents as an acute liver failure within the first weeks or months of life, rapidly leading to death. Sometimes, the hepatopathy, after an initially normal course, is triggered by a viral infection or another unknown event [2] . In AHS, the progression of liver failure is often less rapid, over a period of months to years. Liver function tests may fluctuate and spontaneously reverse, but can also rapidly progress to liver failure. This fulminant deterioration of the liver function often occurs after treatment with hepatotoxic medication such as VPA administered for epileptic seizures. In our first patient, liver function tests became elevated only after VPA was used. However, it is difficult to determine whether this dysfunction is because of the medication or acts as an inherent feature of mitochondrial disease in general, as patients who were not treated with VPA often also develop liver test elevations over time (cf. case 2). Tzoulis et al. [7] interestingly described the clinical spectrum of 26 patients with a mutation in A467T (i.e. the same mutation as in case 3) and/or W748S in PolG, known to cause AHS. Even in this genetically homogeneous group of patients, the phenotypes differ considerably. In 13 of these 26 patients, liver test abnormalities were present, associated with actual liver dysfunction and end-stage liver failure in eight of them. In two of the patients, liver failure was the sole cause of death, in a third together with status epilepticus. One patient received an unsuccessful liver transplantation (LT) and died 1 month later of liver failure. Another received a successful LT, with seizure control achieved with VPA. Four others died of status epilepticus. Statistical comparison of the eight patients with liver failure in the end showed a highly significant association between liver disease and valproate use (P < 0.001). In a general population, B1/37 000 individuals exposed to VPA develops idiosyncratic liver toxicity. One-third of patients with AHS develop liver failure within 3 months of exposure to VPA. Stewart et al. [14] reported how all patients with suspected VPA toxicity enrolled in the Drug Induced Liver Injury Network from 2004 to 2008, more than 50% had heterozygous PolG substitutions associated with a more than 20-fold increased risk of VPA-induced liver injury. The variation in the evolution of the disease process still remains an intriguing aspect of mitochondrial disorders. The first accurate correlation between genotype and phenotype was discussed by Ashley et al. [15] , describing that the cellular mtDNA content reflects the specific genotype. However, even with one and the same PolG genotype, disease progression and first presenting symptoms are not always predictable as was described by Cohen and Naviaux [5] and shown in Tzoulis et al.'s [7] study. In some patients, liver dysfunction is the first symptom; in others, liver dysfunction is a rather late feature. In MNGIE, liver involvement is not considered a typical feature, but it is described nonetheless. Nishino et al. [10] noted hepatopathy in five of 20 patients with MNGIE. Four patients had a fatty liver attributed to parenteral nutrition and one patient had cryptogenic cirrhosis.
Diagnosis
The diagnosis of mitochondrial diseases is made on the basis of a combination of clinical presentation, biochemistry/ enzyme activity, histopathology, and genetic testing. Clinical presentation most often includes dysfunction of multiple organs. As was stated before, organs that depend considerably on ATP will suffer the most, such as muscle, the central and peripheral nervous system, and the liver. The typical features of AHS and MNGIE are described above. In the context of mitochondrial hepatopathy, suspicion is especially indicated in patients who develop liver-related problems after initiation of VPA and in patients in whom liver disease is accompanied by neurological problems. As illustrated in cases 1, 3, and 4, lactic acidemia is a frequently found feature of mitochondrial disease. Defects in the respiratory chain will cause incomplete oxidation of carbohydrates, fatty acids, and amino acids, resulting in the accumulation of intermediate metabolites such as lactate, typically in the postprandial period, and normalizing during fasting [16] . Although lactic acidemia is a frequent finding in mitochondrial diseases, it is not an essential feature for diagnosis, and especially not in patients with AHS, as patients with this disorder tend to have absent lactic academia more often. Other useful screening tests include lactate/pyruvate proportion (elevated in patients 3 and 4), arterial 3-hydroxybutyrate/acetoacetate proportion, plasma amino acids (alanine) (elevated in patient 2), paradoxical increase in plasma ketone bodies or lactate after meals, and oral glucose load (2 g/kg) with an elevated lactate/pyruvate ratio when repeated each 15 min for 90 min. As in case 2, elevated urinary lactate and tricarboxylic acid cycle intermediates such as succinate, fumarate, and malate can also be suggestive [4] .
A sensitive method of documenting altered mitochondrial function is the direct measurement of mitochondrial respiration, which should still be performed in all patients suspected of having mitochondrial hepatopathy. Analysis of oxygen consumption in fresh mitochondrial-enriched fractions of tissues can be carried out by polarographic studies in the presence of a series of respiratory substrates to define the site of the respiratory impairment. However, these tests require isolation of mitochondria from fresh tissue, which is not available in most centers [4] . A valuable alternative is the direct measurement of the enzymatic activity of each of the respiratory chain complexes in frozen tissues. Our second patient indeed showed decreased activity of respiratory chain complex II and III in frozen liver tissue. Activity of the respiratory chain complexes, however, was normal on a muscle biopsy of our fourth patient. It is important to emphasize that these findings may be restricted only to affected tissue, meaning that if only the liver is involved, enzymology on skeletal muscle or skin fibroblasts will show no defects. This may seem obvious, but especially in critically ill patients or newborns, liver biopsy will not be the first conventional diagnostic approach. Less invasive techniques using cultured skin fibroblasts or skeletal muscle, however, can falsely lead to the exclusion of mitochondrial disease. When MNGIE is suspected on the basis of the clinical presentation, as in our fourth patient, enzyme activity of the TP enzyme can be measured straight away.
Molecular diagnostics should be restricted to patients showing sufficient clinical and biochemical indications for an underlying mitochondrial disorder. The overall strategy at the moment is to order mutation analysis for the gene or genes involved in clear-cut mitochondrial syndromes, and in the absence of a clear-cut syndrome, to screen for mtDNA point mutations and PolG mutations in first line. In parallel, Southern blot analysis or quantitative PCR can show decreased mtDNA content in tissues affected by an MDS [17] . When these examinations yield no definite diagnosis, the orientation of the molecular diagnostic testing is highly specialized (beyond the scope of this paper) and should be adapted to the need for a definite diagnosis in the particular case and the available budget.
Mitochondrial hepatopathies can show a broad variety of histopathological findings. Microvesicular and macrovesicular steatosis are a common feature, as seen in cases 1, 2, and 4, even in the early stages without associated elevated liver function tests. Over time, cholestasis, bile duct proliferation, hepatocyte swelling, hepatocellular necrosis, lobular inflammation, portal fibrosis, and eventually cirrhosis can be found [2] , as was seen in cases 1, 2, and 4. Pseudoacinar formation is noted to be prominent in Navajo neurohepatopathy [18] , and hemosiderosis of the liver is noted among other in MDS [19] . Copper accumulation in the liver, as found in our first patient, has not been noted before in any other patient with AHS. Unfortunately, none of these features are diagnostic for mitochondrial disease. We recently described a previously asymptomatic 6-month-old baby with acute liver failure showing clear features of autoimmune hepatitis on liver biopsy, but without autoantibodies or elevated immunoglobulin G [20] . Later on, when the patient developed epileptic seizures, AHS was genetically confirmed, again proving that not only the heterogeneity of the clinical findings but also of the histopathological investigations can be very misleading. Hence, we should be very careful not to exclude mitochondrial hepatopathy too easily. Light microscopic examination typically shows ragged-red fibers in muscle tissue and increased numbers of hepatocellular mitochondria. Other possible investigations more specifically for AHS include characteristic electroencephalogram findings (high-amplitude slow activity with polyspikes), asymmetric abnormal visualevoked responses, and low-density areas or atrophy in the occipital or temporal lobes on CT scanning of the brain [21] . Also, magnetic resonance spectroscopy can demonstrate impaired energy metabolism in certain areas of the brain correlated with neurological symptoms. The latter investigation is especially sensitive for lactate detection in CSF [8] . In the last few years, several nuclear and mitochondrial genes have been discovered to play a role in the most frequent mitochondrial disorders, making selective screening in nuclear DNA or even fulllength sequencing of mtDNA an increasingly efficient screening tool in the diagnostic process. Although mtDNA mutations more frequently seem to be associated with neuromuscular disorders, most mitochondrial hepatopathies, in contrast, are caused by nuclear rather than mtDNA mutation [2, 22] . Nguyen et al. [23] noted that PolG DNA testing can accurately diagnose AHS in 87% of all cases. The Ala467Thr mutation, as found in our third patient, is the most common mutation causing AHS and is present in 65% of the patients. However, for several other mitochondrial disorders, genetic testing is still limited, leaving an estimated 60-70% of patients with an unconfirmed tentative diagnosis.
Therapy
Therapeutic possibilities are very limited. A causal treatment does not exist for most mitochondrial diseases, but symptomatic therapy with antiepileptics, pacemaker implantation, or nutritional support can relieve some of the symptoms. Hepatotoxic medication such as VPA that was used as first-line therapy in patients 1 and 3 should, however, be avoided because of their ability to precipitate liver dysfunction in AHS. Supportive nutritional supplements and pharmacologic therapies have been widely used in patients with mitochondrial disorders, as well as in all four of our patients, with varying degrees of success. A Cochrane analysis of 2006 concluded that there is no clear evidence suggesting a benefit of any medical therapy in mitochondrial disorders [20] . It should be noted that most of the therapeutic trials reported were conducted primarily in the myopathic forms of mitochondrial disorders [24] . There is little reported experience on medical therapies in mitochondrial hepatopathies [2] . Providing prognostic information, genetic counseling, and broad paramedical support still remain the essential cornerstones of management of patients with mitochondrial disease and their families.
LT in patients with mitochondrial disorders is still a controversial topic because of the multisystemic nature of these disorders and the observation that the involvement of other organ systems may not become evident until after LT [16, 17] . Only rarely is the liver the only organ involved. In these patients, successful LT may indeed lead to a cure for life [25] . Mindikoglu et al. [26] , in contrast, recently found that children who underwent LT for VPA-induced acute liver failure had a significantly lower probability of survival than children with non-VPA drug-induced acute liver failure, concluding that VPAinduced acute liver failure should be a contraindication for LT, even in the absence of documented mitochondrial disease. Although there have been successful LT in patients who did not develop extrahepatic symptoms during the rest of their life, most patients do have associated muscular or nervous system involvement. By now, it has become generally accepted that any extrahepatic symptoms form an absolute contraindication for LT [27, 28] . A thorough evaluation of all possibly affected organs therefore remains essential. This can be particularly challenging in patients presenting with acute liver failure and associated hepatic encephalopathy when a decision needs to be made urgently, sometimes before diagnostic testing can be completed [2, 28] . Brain biopsy as well as liver biopsy is often not an option if there is already coagulopathy associated with liver failure. CSF lactic acid levels, compared with blood lactate, may be suggestive of central nervous system involvement, but does not constitute proof. In addition, patients presenting with liver failure often have increased lactate levels because of liver failure itself. Summarizing the reported experience, overall survival appears to be less than 50% [27] [28] [29] . Therefore, improved diagnostic techniques and predictive biomarkers to aid the selection of the best candidates for LT are certainly needed [2] .
During the last few years, a new therapeutic perspective has been explored for patients with MNGIE. Allogeneic hematopoietic stem cell transplantation (HSCT) has been performed in nine patients using different protocols with varying success. The rationale behind this is as follows: as cellular and plasma thymidine and deoxyuridine levels appear to be in equilibrium among all body compartments, correction of the TP deficiency in a readily accessible compartment such as blood may be sufficient to eliminate the toxic nucleosides and to control the disease [30] . In all patients, a rapid normalization of TP activity as well as a reduction or even disappearance of plasma thymidine and deoxyuridine were observed. However, an objective clinical benefit from HSCT for patients with MNGIE has not yet been proven. In contrast, Haraguchi et al. [27] described a significantly higher TP activity in mouse liver and small intestine than in other tissues. Perhaps in the future, LT could become a possible alternative for HSCT with the same rationale.
Conclusion
The broad spectrum of phenotypical presentations of mitochondrial diseases is largely responsible for a delayed correct diagnosis. Blind treatment of the initial symptoms and the difficulties of mitochondrial enzymatic and molecular investigations remain important pitfalls [23] . The consequences of this misdiagnosis and hence the inappropriate use of certain treatments, such as liver challenging anticonvulsant drugs, can be life threatening. We emphasize the importance of the mere suspicion of a mitochondrial disease in patients with unexplained liver failure or cirrhosis, especially when caused by VPA or when associated with neurological symptoms. Because the first symptoms of mitochondrial diseases do not always present within the first years of life and because several organ systems may be involved, physicians of all medical fields should be aware of these disorders. As the cumulative frequency of the autosomal recessive mutations in PolG approaches 1% in some populations, with a calculated silent carrier frequency of almost 2% [5] , a correct diagnosis is not only important for the patient but also for all family members, who can have an increased reproductive risk.
